Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,828.70 | 2.30 | 0.03% |
CAC 40 | 7,766.71 | 43.24 | 0.56% |
DAX 40 | 24,206.91 | 133.24 | 0.55% |
Dow JONES (US) | 44,335.55 | 70.81 | -0.16% |
FTSE 100 | 8,854.18 | 47.65 | 0.54% |
HKSE | 24,148.07 | 260.24 | 1.09% |
NASDAQ | 20,466.20 | 53.68 | 0.26% |
Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
S&P 500 | 6,237.98 | 8.00 | 0.13% |
S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
SSE Composite Index | 3,497.48 | 24.35 | 0.70% |